Steven Gannon - Mar 7, 2024 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role: Director
Signature: /s/ Nathaniel Adams, Attorney-in-fact
Stock symbol: XENE
Transactions as of: Mar 7, 2024
Transactions value $: -$601,615
Form type: 4
Date filed: 3/8/2024, 05:28 PM
Previous filing: Jun 14, 2023
Next filing: Jun 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XENE	Common Shares	Sale	-$46.5K	-1K	-6.67%	$46.45	14K	Mar 7, 2024	Direct
transaction	XENE	Common Shares	Sale	-$231K	-5K	-35.71%	$46.25	9K	Mar 7, 2024	Direct
transaction	XENE	Common Shares	Sale	-$232K	-5K	-55.56%	$46.30	4K	Mar 7, 2024	Direct	F1
transaction	XENE	Common Shares	Sale	-$92.4K	-2K	-50%	$46.20	2K	Mar 7, 2024	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.3025 to $46.3675, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F2	The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.20 to $46.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Content

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.3025 to $46.3675, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.20 to $46.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.